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ABSTRACT 
Background: An antineoplastic agent, mitoxantrone (MX) is used to treat 
neurologic disability and/or educe the frequency of clinical relapses in patients 
with secondary progressive, progressive relapsing, or worsening relapsing- 
remitting multiple sclerosis (MS). Based on a MEDLINE search for literature con- 
cerning the use of IV MX in patients with secondary progressive MS (SPMS), 
there is a paucity of data to identify the clinical characteristics of responders. 
Objective: The aim of this study was to monitor the effects of IV MX in 
patients with SPMS and varied clinical characteristics whose condition contin- 
ued to worsen despite receiving IV methylprednisolone tr atment. 
Methods: This prospective, open-label study was conducted at the Multiple 
Sclerosis Clinic, Center for Neurologic Disorders, Milwaukee, Wisconsin. Male 
and female patients aged ~18 years with SPMS whose neurologic ondition, as 
assessed using routine neurologic examination, worsened espite at least one 
5-day course of IV methylprednisolone treatment (1g/d) were enrolled. Patients 
received premedication with an antiemetic and IV MX 12 mg/m 2every 12 weeks 
for up to 2 years, with a total cumulative dose not to exceed 96 mg/m 2. All pa- 
tients were followed up for 1 year after treatment cessation. Efficacy was as- 
sessed at baseline, end of treatment, and 1-year follow-up using the Extended 
Disability Status Scale (EDSS) (which measures the functional disability level) 
(0 -- normal findings on neurologic examination to 10 -- death from MS compli- 
cations). Tolerability was assessed before, during, and immediately after each 
infusion and at 2 weeks after each infusion, using direct questioning of, and 
spontaneous reporting by, the patients; physical examination; and laboratory 
assessments. Cardiac multigated acquisition scanning was performed at base- 
line and every 24 weeks during the treatment period. 
Results: Forty-eight patients were enrolled (28 women, 20 men; mean [SD] 
age, 47.6 [8.6] years; mean [SD] disease duration, 12.5 [6.0] years; mean [SD] 
baseline EDSS score, 6.9 [1.2]). Twenty-three patients completed the entire 
course of treatment; the remaining 25 were withdrawn after 1 year of treatment 
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due to lack of efficacy (22 patients), asymptomatic cardiac ejection fraction 
<40% (2), and severe septicemia and worsening of MS requiring extended respi- 
ratory support and hospitalization (1). Patients who completed only 1 year of 
treatment were younger compared with those who completed 2 years (mean 
age, 45.2 vs 50.1 years; P < 0.05). No significant change in mean EDSS score was 
found at the end of treatment or at 1-year posttreatment follow-up. In patients 
whose disability improved by >0.5 on the EDSS (11 patients at 1 year; 5 patients 
at 2 years), the degree of improvement oted at 1-year follow-up in patients 
with a baseline EDSS score 3.0 to 5.5 versus 6.0 to 7.5 and 8.0 to 9.0 was signifi- 
cant (both, P < 0.05). Severe adverse ffects occurred in 14.6% of patients and 
included marked leukopenia (peripheral white blood cell count, <100 cells/pL) 
with urosepsis, requiring hospitalization i 7 patients, 1 of whom developed 
severe septicemia and worsening of MS, requiring >4 weeks of respiratory sup- 
port. Cardiac ejection fraction decreased to <40% in 2 patients after 1 year of 
treatment ( otal dose, 48 mg/m2). These 2 patients were asymptomatic, but the 
investigators decided to discontinue treatment. Cardiac function returned to 
normal range (but not to near-baseline l vels) within 12 weeks after treatment 
cessation. Although all patients were premedicated with antiemetics, 10 (20.8%) 
reported mild nausea (treated with repeat administration f antiemetics), and 2 
of 16 (12.5%) premenopausal patients reported slightly increased bleeding dur- 
ing menstruation after 1 year of IV MX therapy, requiring no medical therapy or 
adjustment in the treatment protocol. 
Conclusions: Based on the results of this study in this small group of pa- 
tients with worsening SPMS, IV MX treatment for up to 2 years was not asso- 
ciated with a significant change in EDSS score at the conclusion of treatment or 
1 year after treatment cessation. (Curr Ther Res Clin Exp. 2006;67:55-65) Copy- 
right © 2006 Excerpta Medica, Inc. 
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INTRODUCTION 
An antineoplastic agent, mitoxantrone (NIX) was approved by the US Food and 
Drug Administration (FDA) in 2000 for the treatment of neurologic disability 
and/or reduction of the frequency of clinical relapses in patients with second- 
ary progressive, progressive relapsing, or worsening relapsing-remitting multi- 
ple sclerosis (MS)3 This approval was based on the results from a multicenter, 
randomized, placebo-controlled, clinical trial of MX in 194 patients with second- 
ary progressive MS (SPMS) or progressive relapsing MS, conducted by Hartung 
et al. 2 Patients were randomly assigned to 1 of 3 groups: IV MX 5 or 12 mg/m 2or 
placebo (control). Over 2 years, the mean (SD) cumulative doses in the groups 
receiving the 5- and 12-mg/m 2 doses were 37.2 (7.7) and 82.6 (23.1) mg/m 2, 
respectively. A significant treatment effect was detected for the primary out- 
come measure, a multivariate comparison of the 12-mg/m 2 and control groups 
(P < 0.001). The preplanned ordered analysis of each of the 5 components ofthe 
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composite outcome showed significant treatment effects for mean change from 
baseline in Extended Disability Status Scale (EDSS) 3 (which measures the func- 
tional disability level) (0 = normal findings on neurologic examination to 10 = 
death from MS complications), change in ambulation index 4 (0 -- asymptomatic 
to 9 = restricted to wheelchair), number of relapses requiring glucocortico- 
steroids, time to first relapse, and change in standardized neurologic status. 
IV MX was generally well tolerated. Minor adverse ffects (AEs) included nau- 
sea (76%), mild alopecia (61%), menstrual disorder (61%), urinary tract infec- 
tion (32%), and amenorrhea (25%). No serious AEs were reported. Based on a 
MEDLINE search for literature concerning the use of IV MX in patients with SPMS, 
there is a paucity of data to identify the clinical characteristics of responders. 
The aim of the present study was to monitor the effects of IV MX in patients 
with SPMS and varied clinical characteristics whose condition continued to 
worsen despite at least one 5-day course of IV methylprednisolone. 
PATIENTS AND METHODS 
This prospective, open-label study was conducted at the Multiple Sclerosis 
Clinic, Center for Neurologic Disorders, Milwaukee, Wisconsin. Because this 
study only monitored the clinical course of MS and the tolerability of IV MX and 
in patients receiving FDA-approved MX, the need for a formal review by our 
institutional research review board was waived. 
Inclusion and Exclusion Criteria 
Male and female patients aged _>18 years with SPMS (diagnosed and followed 
up by a neurologist at the clinic) whose condition worsened espite at least one 
5-day course of IV methylprednisolone (1 g/d) and who met the FDA-approved 
guidelines for IV MX treatment 1 were invited to participate in the study. All 
males and premenopausal females who would not practice ffective birth con- 
trol and/or those who were believed by the evaluating oncologist to be at risk 
for cancer 0e, those previously treated with cytotoxic drugs and/or who had a 
strong family history of cancer) were excluded. 
All patients were informed of the potential short- and long-term drug compli- 
cations, including cancer. Written informed consent was obtained from patients 
who agreed to participate in the study, informing them of the intent to collect 
the clinical data and to record AEs while they received MX as per the FDA- 
approved guidelines. 1 
Study Drug Administration 
Every 12 weeks, just before study drug administration, patients were pre- 
medicated with an available oral antiemetic (ondansetron 4 mg or prochlorper- 
azine 5 mg). Patients received IV MX 12 mg/m 2 administered every 12 weeks for 
up to 2 years, with a total cumulative dose not to exceed 96 mg/m 2. The drug 
was diluted in 100 mL of isotonic saline and administered at 100 mL/h through 
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an 18-gauge venous angiocatheter placed in the antecubital vein. Drug infusion 
was carried out by a nurse certified in chemotherapy. All patients continued 
any medications they were receiving. 
All patients underwent clinical assessment and counseling concerning poten- 
tial AEs and complications of IV MX treatment by an oncologist to ensure that 
the drug would be well tolerated in each patient. Patients were instructed to 
consult he oncologist if complications developed uring treatment. 
Efficacy Assessment 
Laboratory Analysis 
Immediately before and 2 weeks after each infusion, a complete blood and 
platelet count, pregnancy test, liver function tests, serum chemistry, and urinal- 
ysis were completed. Cardiac function was monitored using cardiac ejection 
fractions found on multigated acquisition (MUGA) scanning obtained at base- 
line and every 24 weeks for up to 2 years of treatment. 
Clinical Assessment 
At baseline and every 12 weeks during the 2-year treatment period, at the 
conclusion of treatment, and 1 year after the conclusion of treatment, clinical 
disability was assessed using the EDSS. 3 The primary outcome of this study was 
the change in the EDSS score. Responders were defined as patients who 
achieved an improvement of ---0.5 on the EDSS. 3 Clinical variables uch as age, 
sex, disease duration, duration of MX treatment, and severity of disability were 
examined for an association with a change from baseline EDSS score. 
Subanalysis 
Because patients were to discontinue all nonstudy treatments during the study 
period, we compared the baseline characteristics and clinical outcomes of pa- 
tients receiving immunomodulating drug therapies (IMDTs) at baseline. A sub- 
group analysis of patients who completed 2 years of therapy versus 1 year also 
was performed. Finally, we looked at the clinical characteristics of the responders 
(patients who achieved improvement of ->0.5 on the EDSS with IV MX treatment). 
Tolerability Assessment 
Tolerability was assessed by the treating nurse before, during, and immedi- 
ately after each infusion and at 2 weeks after each infusion, using direct ques- 
tioning of, and spontaneous reporting by, the patients; physical examination; 
and laboratory assessments. Cardiac MUGA scanning was performed at base- 
line and every 24 weeks during the treatment period. 
Statistical Analysis 
SAS (SAS Institute Inc., Cary, North Carolina) was used for the data analysis. 
A 2-tailed P value <0.05 was required for statistical significance. A paired t test 
was used to compare changes in EDSS score before and after treatment. Analysis 
58 
B.O. Khatri et al. 
of variance was used to test for significant differences between categories of 
treatment duration, age, EDSS score, and number of treatments. Logistics re- 
gression analysis was used to determine whether age, sex, duration of disease, 
or duration of MX treatment were predictive of treatment response. The power 
to detect a significant change in the EDSS score of 0.3 for the subjects in this 
study was 0.82. Tolerability was not formally analyzed. 
RESULTS 
Fifty-two patients with SPMS were screened. Of these, 4 were excluded (3 pa- 
tients had previously been treated with cyclophosphamide and were considered 
at risk for cancer by the oncologist, and 1 patient had a history of myocardial 
infarction). Forty-eight patients (28 women, 20 men) received IV MX treatment. 
The baseline clinical characteristics of the patients were as follows: mean 
(SD) age, 47.6 (8.6) years (range, 23-60 years); mean (SD) disease duration, 
12.5 (6.0) years (range, 1-26 years); and mean (SD) EDSS score, 6.9 (1.2) 
(range, 3-9) (Table I). Thirty-one (64.6%) patients were receiving IMDTs 
at baseline and throughout the study (interferon-131a, 17 patients; glatiramer 
acetate, 10; interferon-131b, 4). No significant differences in baseline clinical 
characteristics (age, sex, duration and severity of disease) were found between 
patients who received IMDTs and those who did not. 
The efficacy results at the completion of treatment and at 1-year follow-up 
are shown in Table II. Of 48 patients, 23 had completed the entire 2-year course 
of treatment, whereas the remaining 25 were withdrawn after 1 year of treat- 
ment. The reasons for withdrawal included lack of efficacy (22 patients), asymp- 
tomatic ardiac ejection fraction <40% (2), and severe septicemia nd worsen- 
ing of MS requiring extended respiratory support and hospitalization (1). No 
significant changes from baseline in EDSS scores were found at treatment con- 
clusion or 1-year posttreatment follow-up in this group of patients. Subgroup 
analysis of patients who completed 2 years of therapy versus 1 year is summa- 
rized in Table III. Patients who completed only 1 year of therapy were younger 
(mean age, 45.2 vs 50.1 years; P < 0.05), but their mean disease duration (11.9 
vs 13.4 years) and mean EDSS score (6.8 vs 7.0) were statistically similar to 
those in patients whose duration of treatment was 2 years. There were no sig- 
nificant changes from baseline in mean EDSS scores at conclusion or at 1-year 
posttreatment follow-up (Table IV). The most noticeable prediction of improve- 
ment appeared to be the severity of disability at the time of treatment. No sig- 
nificant correlation was found between clinical outcomes in patients receiving 
concomitant IMDTs and those not receiving them. In responders (11 patients at 
1 year; 5 patients at 2 years), the degree of improvement oted at 1-year follow- 
up in patients with a baseline EDSS score of 3.0 to 5.5 versus 6.0 to 7.5 and 8.0 
to 9.0 was significant (both, P < 0.05). The logistic regression analysis howed 
that only age (<40 years) was associated with an improvement in EDSS (odds 
ratio = 9.5; P < 0.05). 
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Table I. Baseline demographic and clinical characteristics of 
the study patients (N = 48). 
Characteristic Value 
Age, y 
Mean (SD) 47.6 (8.6) 
Range 23-60 
Age group, no. (%)* 
23-40 y 9 (18.8) 
41-50 y 18 (37.5) 
51-60 y 21 (43.8) 
Sex, no. (%) 
Female 28 (58.3) 
Male 20 (41.7) 
Disease duration, y 
Mean (SD) 12.5 (6.0) 
Range 1-26 
Disease duration, group, no. (%)* 
1-<8 y 12 (25.0) 
9-<15 y 21 (43.8) 
16--<26 y 15 (31.3) 
EDSS t score 
Mean (SD) 6.9 (I .2) 
Range 3-9 
EDSS category, no. (%)* 
3.0-5.5 6 (12.5) 
6.0-7.5 33 (68.8) 
8.0-9.0 9 (i 8.8) 
Receiving IMDT, no. (%) 31 (64.6) 
Interferon-l~la 17 (35.4) 
Glatiramer acetate I0 (20.8) 
Interferon-~1 b 4 (8.3) 
EDSS = Extended Disability Status Scale; IMDT = immunomodulating drug 
therapy. 
*Percentages do not total 100% due to rounding. 
tScale3:0 = normal findings on neurologic examination to 10 = death from 
multiple sclerosis complications. 
Tolerabi l i ty  
Severe AEs included leukopenia (peripheral white blood cell count <100 cells/pL) 
with urosepsis (positive blood cultures and urinary tract infection) requiring 
hospitalization i  7 (14.6%) patients. In 1 patient (female; age, 51 years; baseline 
EDSS, 7.5; disease duration, 13 years), marked leukopenia and urosepsis devel- 
oped, followed by severe septicemia, nd she progressed to septic shock and 
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Table II. Extended Disability Status Scale* (EDSS) scores before (baseline) 
and after treatment with IV mitoxantrone 12 mg/m 2 q12w and at 
1-year follow-up in patients with secondary progressive multiple 
sclerosis (MS) (N = 48). 
EDSS Score, 
Time Point Mean (Range) Change P 
Baseline 6.91 (3-9) - - 
End of treatment 6.97 (2-9) 0.06 >0.30 
1 -Year follow-up 7.16 (4-9) 0.19 0.06 
*Scale3:0 = normal findings on neurologic examination to 10 = death from MS 
complications. 
worsening of MS requiring respiratory support for >4 weeks. This patient even- 
tually recovered, but her EDSS score remained 8.0 at 2-year follow-up. In 6 addi- 
tional patients, leukopenia occurred (typically -2 weeks after infusion), requiring 
hospitalization and SC injection of filgrastim as prescribed by the oncologist. 
Urinary tract infection developed in all 6 of these patients during the study, 
requiring -5 to 7 days of hospitalization and IV antibiotics. However, all 6 pa- 
tients recovered and continued to receive IV MX infusions every 12 weeks. 
Cardiac ejection fraction decreased to <40% in 2 patients after 1 year of treat- 
ment (total dose, 48 mg/m2). The patients were asymptomatic, but the investi- 
gators decided to discontinue treatment. Cardiac function returned to normal 
Table III. Demographic and clinical characteristics of patients who completed 1 or 
2 years of treatment with IV mitoxantrone 12 mg/m ~ q12w for secondary 
progressive multiple sclerosis (MS). 
1 Year 2 Years 
Characteristic (n = 25) (n = 23) P 
Age, mean (range), y 45.2 (23-59) 50.1 (40-60) <0.05 
Disease duration, mean, y 11.9 13.4 <0.35 
EDSS* score, mean (range) 
Baseline 7.0 (3.0-9.0) <0.50 
Completion of treatment 7.2 t (4.0-9.0) <0.40 
Change from baseline +0.17 NS 
% Change from baseline +2.40 NS 
1-Year follow-up 7.3 (6.0-9.0) NS 
Change from treatment completion +0.35 NS 
6.8 (4.0-8.5) 
6.8 (2.0-9.0) 
-0.40 
-0.58 
7.0 ~ (4.0-8.5) 
+0.16 
EDSS = Extended Disability Status Scale. 
*Scale3:0 = normal findings on neurologic examination to 10 = death from MS complications. 
tp < 0.25 versus baseline. 
~P < 0.20 versus baseline. 
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Table IV. Relationship between baseline clinical characteristics and Extended 
Disability Status Scale* (EDSS) scores after treatment with IV mitoxantrone 
12 mg/m 2 q12w in patients with secondary progressive multiple sclerosis 
(MS) (N = 48). 
Change in Change in 
EDSS Score EDSS Score 
from Baseline from Baseline 
to Treatment to 1-Year 
No. of Completion, No. of Follow-Up, 
Characteristic Patients Mean (SD) Patients Mean (SD) 
Sex 
Female 28 0.09 (0.87) 28 0.29 (0.82) 
Male 20 0.03 (0.20) 20 0.20 (0.62) 
Treatment duration 
I Year 25 -0.41 (0.64) 25 0.16 (0.55) 
2 Years 23 0.17 (0.70) 23 0.35 (0.90) 
Age, group, y 
23-40 9 -0.39 t (0.96) 9 0.00 (0.56) 
41-50 18 0.08 (0.19) 18 0.33 (0.73) 
51-60 21 0.24 t (0.74) 21 0.29 (0.82) 
Disease duration, y 
1--<8 12 -0.13 (0.64) 12 0.13 (0.57) 
9--<15 21 0.12 (0.85) 21 0.36 (0.87) 
16----26 15 0.1 3 (0.35) 15 0.20 (0.68) 
Baseline EDSS category 
3.0-5.5 6 -0.20 (I .83) 6 0.92 (I .28) 
6.0-7.5 33 0.08 (0.31) 33 0.24~ (0.59) 
8.0-9.0 9 0.17 (0.35) 9 -0.1 7~ (0.50) 
*Scale3:0 = normal findings on neurologic examination to I 0 = death from 
tp < 0.05 versus age group 41 to 50 years. 
~P < 0.05 versus baseline EDSS category 3.0 to 5.5. 
MS complications. 
range (but not to near-baseline l vels) within 12 weeks after treatment cessa- 
tion. Extravasation of IV MX--an AE of administration--occurred in 1 patient, 
causing significant cellulitis, but this effect eventually healed without any 
complications, and the patient continued to participate in the trial. Although 
all patients were premedicated with an antiemetic, 10 (20.8%) reported mild 
nausea that was treated with repeated administration of antiemetics. Two of 
16 (12.5%) premenopausal patients reported slightly increased bleeding dur- 
ing menstruation after 1 year of IV MX treatment but did not require medical 
therapy or adjustments in the treatment protocol. The frequency and severity 
of AEs did not correlate with any of the clinical parameters studied (age, sex, 
duration and severity of disability) (Table 10. 
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Table V. Adverse effects with IV mitoxantrone 1 g/d in patients 
with secondary progressive multiple sclerosis (N = 48). 
No. (%) 
Adverse Effect of Patients 
Nausea 10 (20.8) 
Leukopenia 7 (14.6)* 
Urosepsis 7 (14.6) 
Menstrual irregularity t 2/16 (12.5) 
Decreased cardiac ejection fraction ~ 2 (4.2) 
*Severe in all patients. 
tlncreased bleeding. 
~Assessed using cardiac multigated acquisition scanning. 
DISCUSSION 
In contrast to the positive clinical outcomes found in the trial by Hartung et al 2 
and other previous studies, 5-9 we did not observe any significant changes in 
mean EDSS scores at conclusion or at 1-year posttreatment follow-up. However, 
stabilization of disability might have been attributable to IV MX treatment. 
The baseline clinical characteristics of patients in the present study were dif- 
ferent from those in the study by Hartung et al 2 (mean [SD] EDSS score, 6.91 
[1.24] vs 4.59 [1.01]; mean [SD] disease duration, 12.5 [6.0] vs 9.64 [6.66] years; 
mean [SD] age, 47.6 [8.6] vs 39.96 [7.6] years), which might account for the dif- 
ferences observed in clinical outcomes. Subgroup analysis of the patients in the 
present study suggested poorer outcomes in patients who were older (aged 
___40 years) and had increased isability at the time of treatment initiation. The 
results of our study suggest hat younger patients (aged <40 years) and those 
with lower EDSS scores (<5.5) are more likely to improve with IV MX compared 
with their older counterparts. Although the number of younger patients in our 
study was small (n = 12), the improvement from baseline in EDSS score was sig- 
nificant (P < 0.05). This finding supports those from a review of an early pivotal 
study in 60 patients, 2 in which the mean age was -40 years and mean EDSS 
score at baseline was <5. Although the present study was smaller, it provides 
information in support  of using IV MX in a select group of patients (aged 
<40 years and EDSS score <5.5). 
In contrast o the absence of any major or life-threatening AEs associated 
with IV MX 12 mg/m 2 administered every 12 weeks in previously published 
reports, 2,5,6 considerable AEs were found in this study. Seven patients with 
leukopenia nd urosepsis required hospitalization. One of these patients 
required >4 weeks of acute and subacute hospitalization as a result of MS wors- 
ening 2 weeks after IV MX infusion. Also of concern was the significant but 
asymptomatic reduction in cardiac ejection fraction to <40% in 2 younger (aged 
41 and 43 years) patients with no history of cardiovascular dysfunction oted 
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after a cumulative dose of 48 mg/m 2. Recent reports of possible MX-induced 
cardiotoxicity in SPMS 10,11 emphasize the need to perform cardiac MUGA scan- 
ning at baseline and before each infusion. 
Although no cancer or leukemia was found in the present study, reports 12-17 
have found cancer and leukemia in patients with MS treated with IV MX. This 
finding should be considered when prescribing IV MX for the treatment of MS, 
a disease that does not significantly shorten the life span. 18 
Although this study was small, open label, and not powered to assess the 
effectiveness or tolerabil ity of this drug in worsening SPMS, the overall magni- 
tude of AEs outweighed the small gains found in the subgroup of patients (aged 
<40 years and EDSS score <5.5). 
Further studies are warranted to investigate these prel iminary findings. 
CONCLUSIONS 
Based on the results of this prospective, uncontrol led, open-label study in this 
small group of patients with worsening SPMS, IV MX treatment for up to 2 years 
was not associated with a significant change in EDSS score at the conclusion of 
treatment or 1 year after treatment cessation. 
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